2 FTSE 100 growth giants that could fund your retirement

These two rising FTSE 100 (INDEXFTSE:UKX) stocks could help you to a comfortable old age.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

If you’re investing for your retirement, what should you do differently? I’d say nothing at all, because a good retirement investment strategy is simply a good investment strategy.Strategies aimed at maximising your long-term returns have a habit of turning out to be the most successful, whatever your age or plans.

To that end, there are many good stocks that should be good for long-term growth, and today I’m looking at two from the FTSE 100.

A new growth phase

AstraZeneca (LSE: AZN) has suffered a bit in recent years as the loss of patent protection on some key drugs has opened the way for cheap generic competition. Earnings have fallen as a result and the company has been working hard to focus on its core business and reinvigorate its development pipeline. 

You might imagine that the shares have had a few tough years as we await news of a return to earnings growth. But you’d be wrong, as AstraZeneca shares have actually gained 65% over the past five years, to 4,725p today. And over that period, the company has kept on paying dividends of around 5% and better.

So how will AstraZeneca do in a renewed period of sustainable growth? I think it will do very well indeed, and that were are on the verge of exactly that. Analysts seem to think the turnaround in earnings per share should happen in 2018 as the changes made by Pascal Soriot since he took the helm in 2012 are bearing fruit.

As of 2016 results time, 12 new drugs candidates had reached the Phase III stage or were under regulatory review, targeting oncology, cardiovascular and metabolic diseases and respiratory conditions, which are all growing first-world problems. And there are some clear candidates to become the blockbusters of tomorrow.

AstraZeneca shares are on a P/E of 15 on 2018 forecasts, and I reckon that could shrink rapidly over the next 10 years and make the shares look a real bargain today.

A hidden secret

GKN (LSE: GKN) is a company that has largely evaded me so far as its share price has somewhat stagnated in recent years, but while searching for solid growth candidates it has caught my eye. There was a minor dip in 2015, but since the end of 2012 the automotive engineer has grown its earnings per share by 18% — and forecasts suggest a gain of 37% by 2018.

Over the same period, dividends have been modest in the 2%-3% range, but they’re progressive and have been growing well ahead of inflation. That trend is expected to continue, and for me a dividend that is growing reliably in real terms is a very desirable thing.

Results for 2016 showed a 22% rise in revenue, which boosted adjusted pre-tax profit by 12%, and forecasts suggest two more years of earnings growth. And despite a one-off restructuring charge of £39m, the firm reckoned that has resulted in annualised savings of £30m.

We’re looking at a company here that has come through a restructuring phase, has what I see as attractive growth potential over the next decade and more, and whose shares are trading on a forward P/E of only around 10. That looks to me to be a great candidate for a retirement portfolio.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK owns shares of GKN. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

Investing freedom — but inside a pension

Strapped consumers might be cutting back on investing, but they’re still keeping up their pension contributions. The only problem? A…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

Forget gold! I’d rather buy these 3 FTSE high-yielders in a Stocks and Shares ISA

Gold looks like a risky investment to me as the price hits an all-time high. I'm ignoring the fuss to…

Read more »

Young female business analyst looking at a graph chart while working from home
Growth Shares

This 55p UK stock could rise more than 300%, according to a City broker

This UK stock has fallen from above 800p to below 60p. But analysts at Citi believe it’s capable of a…

Read more »

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

I think this FTSE 250 trust has all the right ingredients to lock in long-term profits

Today I'm examining the prospects of a private equity investment trust on the FTSE 250 that caught my attention recently…

Read more »

Young black man looking at phone while on the London Overground
Investing Articles

2 under-the-radar UK shares investors should consider snapping up

Two UK shares have caught the eye of our writer. She explains why investors should be taking a closer look…

Read more »

Investing Articles

Are these 2 ultra-high-yielding income stocks a good buy for me?

These two income stocks often split the debate amongst investors. So what does our writer think of them as potential…

Read more »

Senior woman potting plant in garden at home
Investing Articles

5% yield! This dividend stock could be great for my retirement

Our writer explains why this dividend stock appeals to her as she’s investing to build wealth to enjoy in the…

Read more »

A young Asian woman holding up her index finger
Investing Articles

I’d aim for a second income of £1,000 a month with this super-reliable dividend stock

I think a great way to build a second income stream is by investing in dividend stocks via a Stocks…

Read more »